Oruka Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ORKA | 8SJ.F | 688177.SS | 4564.T | 4594.T | 2162.HK | |
|---|---|---|---|---|---|---|
| Market cap | 6.71B | 1.84B | 7.38B | 6.94B | 5.42B | 20.67B |
| P/E (TTM) | — | — | — | — | — | 23.8 |
| Forward P/E | -35.4 | — | -26.2 | -0.8 | — | 206.8 |
| Price/book | 5.6 | 2.4 | 171.3 | 3.0 | 2.3 | 4.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +264.52% | −40.07% | −34.43% | −26.09% | −35.48% | +8.65% |
| Today | +1.87% | +1.70% | +2.95% | 0.00% | −2.50% | +2.48% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ORKA news ›Nomelcitinib Hits Primary Endpoint in Phase 3 Psoriasis Trial
InventisBio Co.’s nomelcitinib (D-2570) met the primary endpoint and the key secondary endpoint in a registrational Phase 3 clinical trial for moderate-to-severe plaque psoriasis. Nomelcitinib is a Janus kinase homology 2 (JH2)…
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal…
InventisBio’s Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial
BioPharma APAC - InventisBioâs Nomelcitinib Achieves Both Primary and Key Secondary Endpoints in Phase III Psoriasis Trial 03 November 2026 | Tuesday | News InventisBio Co., Ltd. announced t
In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis
1. Nomelcitinib, a tyrosine kinase 2 (TYK2) inhibitor, achieved significantly higher Psoriasis Area Severity Index (PASI) 90 and Physician Global Assessment (PGA) 0/1 response rates than placebo at week 16 (p 2. The company reported no new…
ORKA-001 Clears Skin in 61% of High-Dose Psoriasis Patients at Week 16
ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B psoriasis trial. ORKA-001, an investigational half-life extended interleukin (IL)-23p19 monoclonal…
Oruka Therapeutics Shares Climb 11% as Psoriasis Drug Fully Clears Skin in 61% of Patients in Mid-Stage Trial
Shares of Oruka Therapeutics Inc. rose more than 11% on Monday. The biotechnology company reported that its experimental psoriasis drug completely cleared patients' skin in a majority of cases at its highest dose in a mid-stage trial,…
More from 1 other outlet
Oruka Therapeutics, Inc. Announces Appointment of Todd Edwards to Chief Commercial Officer, Effective August 24, 2026
Oruka Therapeutics, Inc. announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards, age 63, previously served as Executive Vice President and Chief... announced the appointment of Todd…
Transcript : Oruka Therapeutics, Inc. - Special Call
Presentation Operator MessageOperator Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Oruka Therapeutics... Transcript : Oruka Therapeutics, Inc. -…
Oruka Advances ORKA-001 Toward Phase 3 After Positive Psoriasis Data
Oruka Therapeutics (ORKA) reported positive Week 16 Phase 2b EVERLAST-B results for ORKA-001 in moderate-to-severe psoriasis. The high-dose group achieved 61% complete skin clearance (PASI 100) and 86% PASI 90 responses, outperforming…
Oruka Therapeutics Names Chief Commercial Officer
Oruka Therapeutics said late Monday it has appointed Todd Edwards as chief commercial officer, effective Aug. 24. Edwards most recently served as executive vice president and chief commercial... Biotechnology & Medical Research Oruka…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net8
- markets.businessinsider.com8
- stocktitan.net7
- marketscreener.com6
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 40 articles, not a forecast.